Aridis Pharmaceuticals logo
Aridis Pharmaceuticals ARDS

Quarterly report 2023-Q3
added 11-06-2023

report update icon

Aridis Pharmaceuticals Book Value 2011-2026 | ARDS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.
What is included in book value
  • Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
  • Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
Features of the metric
  • Assessment of the company's "real" value
    Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
  • Comparison with market capitalization
    Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
  • Indicator of financial stability
    If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
  • Key component for financial ratios
    Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Aridis Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-24.2 M -13.1 M -8.68 M 3.64 M 26.3 M 11.4 M 13.8 M - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
26.3 M -24.2 M 1.31 M

Quarterly Book Value Aridis Pharmaceuticals

2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-11.8 M -24.2 M -35.8 M -27.9 M -20.4 M -13.1 M -4.16 M -13.5 M -8.56 M -8.68 M -8.68 M -8.68 M -8.68 M 3.64 M 3.64 M 3.64 M 3.64 M 26.3 M 26.3 M 26.3 M 26.3 M 11.4 M 11.4 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
26.3 M -35.8 M -1.67 M

Book Value of other stocks in the Biotechnology industry

Issuer Book Value Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
49 M - 2.43 % $ 254 M germanyGermany
Alector Alector
ALEC
30.6 M $ 2.08 -14.4 % $ 214 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-16.8 M - 2.71 % $ 14 M usaUSA
Altimmune Altimmune
ALT
124 M $ 4.2 -2.67 % $ 298 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
370 M $ 20.24 -3.44 % $ 2.55 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
11.8 M $ 0.8 1.87 % $ 4.36 M chinaChina
Aprea Therapeutics Aprea Therapeutics
APRE
22.7 M $ 0.88 -3.72 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
4.76 M $ 7.2 -1.64 % $ 1.99 M usaUSA
I-Mab I-Mab
IMAB
5.63 B - - $ 866 M chinaChina
Aquestive Therapeutics Aquestive Therapeutics
AQST
-60.2 M $ 4.1 2.37 % $ 356 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
253 M - - $ 40.3 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
5.36 M - -10.17 % $ 12.2 K usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
241 M $ 8.35 1.46 % $ 225 M israelIsrael
Ardelyx Ardelyx
ARDX
167 M $ 6.37 -2.75 % $ 1.54 B usaUSA
Biophytis SA Biophytis SA
BPTS
34.9 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
715 M - - $ 1.01 B usaUSA
argenx SE argenx SE
ARGX
5.5 B $ 756.71 -1.33 % $ 25 B niderlandNiderland
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
-32.1 M $ 10.91 1.58 % $ 394 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
29.5 M - - $ 26.5 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
189 M $ 25.33 -6.1 % $ 3.22 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
2.33 B - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
8.32 M - -18.52 % $ 27.3 M britainBritain
Artelo Biosciences Artelo Biosciences
ARTL
-1.27 M $ 1.15 -3.36 % $ 2.32 M usaUSA
Arvinas Arvinas
ARVN
434 M $ 12.97 -2.3 % $ 920 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
1.39 B $ 61.74 -2.42 % $ 8.26 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
-163 M $ 231.56 -0.83 % $ 5 B danmarkDanmark
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
35.5 M $ 3.39 -1.63 % $ 8.16 B australiaAustralia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
32.8 M $ 1.17 -0.85 % $ 35.2 M usaUSA
Atossa Therapeutics Atossa Therapeutics
ATOS
91 M $ 4.39 -0.9 % $ 553 M usaUSA
Atara Biotherapeutics Atara Biotherapeutics
ATRA
-97.3 M $ 5.01 -7.47 % $ 37.5 M usaUSA
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
581 M $ 14.14 -0.21 % $ 1.9 B canadaCanada
ARCA biopharma ARCA biopharma
ABIO
382 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
109 M - -24.86 % $ 820 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
427 M $ 1.68 -1.75 % $ 429 M britainBritain
Acasti Pharma Acasti Pharma
ACST
66.6 M - 4.01 % $ 150 M canadaCanada
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
439 M $ 4.69 0.21 % $ 395 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
70.7 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
10.6 M - - - russiaRussia
AIkido Pharma AIkido Pharma
AIKI
39.9 M - 1.93 % $ 17.4 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
94.9 M $ 4.54 2.44 % $ 387 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
750 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
234 M - 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
176 M - -0.23 % $ 916 M usaUSA
Axon Enterprise Axon Enterprise
AXON
2.33 B $ 570.5 5.18 % $ 43.2 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
88.3 M $ 162.28 -0.98 % $ 8.07 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
18.9 M - 3.16 % $ 1.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
124 M $ 2.56 -0.58 % $ 16.1 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
54.4 M - 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
113 M - 4.14 % $ 49.1 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
179 M - - $ 2.17 B usaUSA